𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis

✍ Scribed by Wei Gong; Huan Dou; Xianqin Liu; Lingyun Sun; Yayi Hou

Book ID
117948748
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
910 KB
Volume
39
Category
Article
ISSN
0305-1870

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vitro blockade of receptor activator
In vitro blockade of receptor activator of nuclear factor-κB ligand prevents osteoclastogenesis induced by neuroblastoma cells
✍ Donatella Granchi; Ilaria Amato; Luca Battistelli; Sofia Avnet; Sergio Capacciol 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 550 KB

## Abstract Proliferation and differentiation of osteoclasts are regulated by a cytokine system that includes RANKL, which binds 2 receptors: RANK, which activates osteoclast differentiation, and osteoprotegerin (OPG), a decoy receptor that limits RANKL action. We investigated the role of the OPG/R

Effects of disease-modifying antirheumat
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand
✍ Chang-Keun Lee; Eun Young Lee; Son Mi Chung; Se Hwan Mun; Bin Yoo; Hee-Bom Moon 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

## Abstract ## Objective To demonstrate the effects of disease‐modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through their effects on receptor activator of nuclear factor κB (RANK), osteoprotegerin (OPG), and RANK ligand (RANKL). ## Methods Peripheral b

The antirheumatic drug leflunomide inhib
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand–stimulated induction of nuclear factor of activated T cells c1
✍ Makoto Urushibara; Hiroshi Takayanagi; Takako Koga; Sunhwa Kim; Miho Isobe; Yasu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB 👁 2 views

## Abstract ## Objective Suppression of bone destruction is required as part of an effective therapeutic strategy for autoimmune arthritis. Although numerous antirheumatic drugs are in clinical use, little is known about whether they inhibit bone destruction by acting on activated T cells or other

Simvastatin, 3-hydroxy-3-methylglutaryl
Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-κB ligand through modulation of NF-κB pathway
✍ Kwang Seok Ahn; Gautam Sethi; Madan M. Chaturvedi; Bharat B. Aggarwal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 631 KB

## Abstract Simvastatin, an inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase, is a cholesterol‐lowering drug that may play a role in bone metabolism through a mechanism that is not fully understood. Recently, receptor activator of NF‐κB ligand (RANKL), a member of the TNF superfamily, h